Dr. Raj Reddy
President & Chief Executive Officer Canary Global
Seminars
Thursday 16th April 2026
Panel Discussion: Collating the Lessons Learned from FDA Approved Drugs to Inform the Future of GLP-1 Based Therapies & Ensure a Next- Generation of More Patient Centered Approaches
4:00 pm
- Broadening the therapeutic scope of GLP-1s as the new frontier for a wide range of new applications, such as cardiovascular disease, neurodegenerative disorders and ageing, offering patients a more comprehensive approach to health beyond just weight loss
- Enhancing drug delivery for patient success to improve patient adherence through less frequent administration, including once-a-month injections and oral medications, providing a convenient and less intrusive treatment experience that supports longterm adherence
- Integrating a complementary ecosystem of care for collaborative approach of chronic drugs, advanced combinations, and procedural solutions that work together to create a personalized treatment plan for each patient, maximizing chances of achieving sustainable metabolic health
Wednesday 15th April 2026
Advancing Targeted Genetic Therapies with a Dual-siRNA Approach to Disrupt the Current GLL-1 Monopoly for a More Patient-Focused Treatment Diversity
11:00 am
- Moving beyond appetite suppression by leveraging proprietary dual-siRNA technology to target the root genetic drivers of metabolic dysfunction, promoting the ‘browning’ of white fat and significantly enhancing energy expenditure
- Preserving vital lean muscle mass while achieving selective, transformative fat loss, thereby resolving the critical body composition challenges associated with current therapies and securing healthier, more sustainable long-term metabolic outcomes
- Delivering a disruptive, patient-centric treatment option through a targeted genetic approach that offers the potential for infrequent, twice-yearly dosing, fundamentally changing the treatment paradigm and increasing diversity in the next generation of approved drugs
